Alnylam Files IND for RSV Treatment; Breakdown of RNAi Drugs Pipelines | GenomeWeb

Alnylam Pharmaceuticals announced this week that it has submitted to US regulators an investigational new drug application to begin phase I testing of an intranasally delivered RNAi-based treatment for respiratory syncytial virus.

The news comes a little more than a month after Alnylam said it would drop development of its age-related macular degeneration treatment ALN-VEG01 amid competition in the field (see RNAi News, 9/23/2005).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.